|
|
|
| Prognostic value of procalcitonin level in patients with acute exacerbation of severe chronic obstructive pulmonary disease |
| LI Yang1 XIAO Yan-qiu2 LIN Rui-bo3 LIU Ye-zhao1 |
1.Department of Critical Care Medicine,Chaozhou Central Hospital,Guangdong Province,Chaozhou 521000,China;
2.Department of Emergency,Chaozhou Xiangqiao District Chinese Medicine Hospital,Guangdong Province,Chaozhou 521021,China;
3.Department of Cardiology,Chaozhou Central Hospital,Guangdong Province,Chaozhou 521000,China |
|
|
|
|
Abstract Objective To explore the prognostic value of procalcitonin level in patients with acute exacerbation of severe chronic obstructive pulmonary disease.Methods A total of 60 patients with acute exacerbation of severe chronic obstructive pulmonary disease admitted to Chaozhou Central Hospital from January 2016 to May 2019 were selected as the research objects.According to the average peripheral platelet specific volume (PCT) value of healthy people,which was (2.29±0.31) ng/L,they were divided into high procalcitonin level group (30 cases) and low procalcitonin level group(30 cases).The hospital stay,acute physiological and chronic health score (APACHE Ⅱ),high-sensitivity C-reactive protein (hs-CRP) index,mechanical ventilation,and mortality were compared and analyzed between the two groups.Results The hospital stay in the high procalcitonin level group was longer than that in the low procalcitonin level group,the difference was statistically significant (P＜0.05).The APACHE Ⅱscore,hs-CRP,mechanical ventilation rate and mortality in the high procalcitonin level group were higher than those in the low procalcitonin level group,the differences were statistically significant (P＜0.05).Conclusion The patients with acute exacerbation of severe chronic obstructive pulmonary disease with high level of procalcitonin are more serious,have a longer hospitalization time,and have a higher invasive ventilation rate and mortality.Procalcitonin level is used as a guide for clinical treatment options and prognosis judgment in the acute exacerbation of severe chronic obstructive pulmonary disease.
|
|
|
|
|
|
| [13] |
朱林燕，陈莎娜.诱导痰降钙素原和炎症因子在慢性阻塞性肺疾病急性加重期中的价值研究[J].临床肺科杂志，2020，25（1）：50-53.
|
| [14] |
查丽芬，潘慧明，李倩，等.降钙素原在慢性阻塞性肺疾病急性加重期抗感染治疗中临床应用效果分析[J].当代医学，2020，26（5）：175-177.
|
| [15] |
王阿琴.降钙素原在慢性阻塞性肺疾病急性加重期抗感染治疗中的临床应用[J].当代医学，2020，26（5）：74-76.
|
| [16] |
周正华，温保江，龚声宏，等.血清降钙素原、超敏C反应蛋白及D-二聚体联合检测在慢性阻塞性肺疾病急性加重期患者预后预测中的价值[J].结核病与肺部健康杂志，2019，8（4）：289-293.
|
| [10] |
王丽.降钙素原水平与C反应蛋白水平对重症慢性阻塞性肺疾病患者的预测价值[J].现代医学与健康研究（电子版），2019，3（19）：117-118.
|
| [11] |
操蓓蓓，王伟.血清降钙素原水平与ICU患者30 d 死亡率的关系[J].浙江临床医学，2018，20（5）：926-928.
|
| [12] |
刘国栋，何青梅，廖振辉.C反应蛋白和降钙素原检测在重症慢性阻塞性肺疾病患者中的临床应用价值[J].包头医学院学报，2018，34（2）：8-9.
|
| [1] |
牛艳慧，高勇，王鑫，等.降钙素原水平与C反应蛋白对重症慢性阻塞性肺疾病患者的预测价值[J].临床肺科杂志，2015，20（8）：1407-1409.
|
| [2] |
陈美平，杜杰，刘阳珍.血浆降钙素原水平对慢性重症肝炎合并感染的临床诊断价值[J].医学临床研究，2016，33（12）：2458-2460.
|
| [3] |
慢性阻塞性肺疾病急性加重（AECOPD）诊治专家组.慢性阻塞性肺疾病急性加重（AECOPD）诊治中国专家共识（2017年更新版）[J].国际呼吸杂志，2017，37（14）：1041-1057.
|
| [4] |
熊方，谢琪，晏诚.血清降钙素原水平检验在呼吸系统感染治疗中的意义[J].临床医药文献电子杂志，2016，3（38）：7631-7632.
|
| [5] |
池峰，张舒，姚晓阳，等.慢阻肺患者急性加重期病原菌分布及其降钙素原水平分析[J].临床肺科杂志，2016，21（11）：1962-1964.
|
| [6] |
徐云峰.ICU 感染患者降钙素原水平的影响因素及相关性分析[J].感染、炎症、修复，2016，17（3）：135，148.
|
| [7] |
刘俊霞，杨丽丽，李川.老年重症肺部感染患者血清降钙素原水平测定的临床意义[J].基层医学论坛，2016，20（31）：4384-4385.
|
| [8] |
张群英.血清降钙素原水平检验在呼吸系统感染治疗中的临床意义分析[J].心理医生，2016，22（32）：14-15.
|
| [9] |
王青.降钙素原超敏C反应蛋白血嗜酸性粒细胞在慢性阻塞性肺疾病中的临床意义及分析[J].中国药物与临床，2020，20（3）：425-426.
|
|
|
|
